Recursion Pharmaceuticals, Inc.
RXRX
$4.56
-$0.085-1.83%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -62.31% | -41.33% | -29.12% | -44.21% | -42.31% |
| Total Depreciation and Amortization | 72.71% | 49.55% | 54.99% | 103.41% | 120.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 102.37% | 60.25% | 56.90% | 57.14% | 62.04% |
| Change in Net Operating Assets | 88.12% | 24.39% | -39.74% | -45.59% | -47.27% |
| Cash from Operations | -22.75% | -24.81% | -22.97% | -38.09% | -35.24% |
| Capital Expenditure | 33.94% | -14.55% | 19.05% | 58.06% | 64.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 14,927.33% | 14,927.33% | -103.71% | -103.71% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -9,162.50% | -2,763.25% | -1,537.77% | -104.83% | -99.94% |
| Cash from Investing | 2,348.00% | 2,642.62% | -13.78% | -136.34% | -125.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -741.28% | -479.63% | -3,092.63% | -719.15% | -734.78% |
| Issuance of Common Stock | 120.58% | 118.99% | 82.36% | 165.27% | -0.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 117.44% | 117.02% | 80.98% | 164.93% | -1.35% |
| Foreign Exchange rate Adjustments | 5,775.86% | -1,911.70% | 178.19% | -156.25% | 90.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 215.20% | 227.85% | 157.07% | 239.43% | -392.95% |